Ultra-Low-Dose Nivolumab Significantly Improves OS Over Chemotherapy in Pretreated Patients with Solid Tumours By Ogkologos - February 17, 2026 5 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the DELII study Source RELATED ARTICLESMORE FROM AUTHOR Worse Survival Observed Among Patients Diagnosed with Cancer During the First 2 Years of the COVID-19 Pandemic AI-Supported Mammography Screening Shows Favourable Outcomes Compared with Standard Double Reading ESMO Welcomes European Parliament Resolution Marking World Cancer Day MOST POPULAR Navigating Cancer Survivorship as a Transgender or Non-Binary Person May 5, 2021 Can Some Women Treated for Endometrial Cancer Forgo Radiation after Surgery? July 15, 2019 Themes in Improving Supportive Care for People With Cancer: 2022 MASCC... September 1, 2022 ESMO Calls for Cardio-Oncology to Be Integrated into the EU Cardiovascular... September 17, 2025 Load more HOT NEWS We have a Deal: What does the new UK-EU relationship mean... New Cancer Diagnoses Jump at Age 65, Suggesting People Put Off... COVID-19: “We’re having to rebuild and adapt because of coronavirus” Pralsetinib: Measures to Minimise Increased Risk for Tuberculosis
